Press Releases

Webcast Alert: BioMS Medical Corp. Presentation at Informed Investors Biotechnology / Healthcare / Pharmaceuticals Investor Forum to be Webcast on Thursday, August 25, 2005, 11:00 am ET

Edmonton, AB – August 24, 2005 /CCN Matthews/ -- BioMS Medical Corp. (TSX: MS) will present at the following forum:

What: BioMS Medical Corp. (TSX: MS) will give a presentation at Informed Investors Biotechnology / Healthcare / Pharmaceuticals On-line Investors Forum.
The keynote presentation will be from Dr. Adam K. Noah, Research Analyst with Granite Financial Group
When: August 25, 2005 @11:00 AM Eastern Time
Where: http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=89493
How: Live over the Internet—Simply log on to the web at the address above.
Contact: Amanda Stadel, Investor Relations Manager, astadel@biomsmedical.com , (780)413-7152

If you are unable to attend the live event, the forum will be archived and available via the Informed Investors website at http://www.informedinvestors.com/IIF/IIF_Forum.asp?ForumID=89493

BioMS Medical Corp. is a biotechnology company dedicated to the development and commercialization of innovative therapies. The company is focused on three novel therapeutic technologies, all of which have been licensed from the University of Alberta.

BioMS Medical’s lead product, MBP8298, is a promising treatment for multiple sclerosis (MS). With over 2.5 million MS patients worldwide, MBP8298 has the potential to positively affect hundreds of thousands of lives. MBP8298 is currently in a pivotal Phase II/III trial for patients with secondary progressive MS (SPMS). This is the only late stage SPMS clinical trial in the world for a form of the disease for which there are few treatment options.

Additional technologies include HYC750, a potential method for the mobilization of stem cells and neutrophils for the treatment of cancer therapy related side effects, and an equity investment in BioCyDex, a private company developing a unique proprietary drug delivery technology to deliver both existing and novel anti-viral and chemotherapeutic compounds directly into cells for the purpose of improving their effectiveness.

BioMS Medical is a publicly traded company on the Toronto Stock Exchange (TSX:MS)
Source: BioMS Medical Corp.
FORUM CONTACT: Cary Loeser, Informed Investors, 804-327-3407, cloeser@wilink.com
Web site: http://www.informedinvestors.com

This press release may contain forward-looking statements, which reflect the Corporation’s current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Corporation’s ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that dirucotide (MBP8298) will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.